Dose‐Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin‐Coated PGMA Nanoparticles
Abstract
The paradigm of using nanoparticle‐based formulations for drug delivery relies on their enhanced passive accumulation in the tumor interstitium. Nanoparticles with active targeting capabilities attempt to further enhance specific delivery of drugs to the tumors via interaction with overexpressed cellular receptors. Consequently, it is widely accepted that drug delivery using actively targeted nanoparticles maximizes the therapeutic benefit and minimizes the off‐target effects. However, the process of nanoparticle mediated active targeting initially relies on their passive accumulation in tumors. In this article, it is demonstrated that these two tumor‐targeted drug delivery mechanisms are interrelated and dosage dependent. It is reported that at lower doses, actively targeted nanoparticles have distinctly higher efficacy in tumor inhibition than their passively targeted counterparts. However, the enhanced permeability and retention effect of the tumor tissue becomes the dominant factor influencing the efficacy of both passively and actively targeted nanoparticles when they are administered at higher doses. Importantly, it is demonstrated that dosage is a pivotal parameter that needs to be taken into account in the assessment of nanoparticle mediated targeted drug delivery.Keywords
Funding Information
- Australian Research Council
This publication has 43 references indexed in Scilit:
- Annotating MYC status with 89Zr-transferrin imagingNature Medicine, 2012
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401Journal of Clinical Oncology, 2012
- PC3 is a cell line characteristic of prostatic small cell carcinomaThe Prostate, 2011
- Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell ModelsPLOS ONE, 2010
- A Reexamination of Active and Passive Tumor Targeting by Using Rod-Shaped Gold Nanocrystals and Covalently Conjugated Peptide LigandsACS Nano, 2010
- Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticlesProceedings of the National Academy of Sciences, 2009
- Unique patterns of molecular profiling between human prostate cancer LNCaP and PC‐3 cellsThe Prostate, 2009
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences, 2008
- siRNA screen of the human signaling proteome identifies the PtdIns(3,4,5)P3-mTOR signaling pathway as a primary regulator of transferrin uptakeGenome Biology, 2007
- Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivoProceedings of the National Academy of Sciences, 2006